ストックスクリーナーアプリを入手
1.96
5.38%
0.10
プレマーケット:
1.93
-0.03
-1.53%
前日終値:
$1.86
開ける：
$1.75
24時間の取引高:
12.07M
Relative Volume:
2.41
時価総額：
$641.55M
収益：
-
当期純損益:
$-63.08M
株価収益率:
-7.2593
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
+5.38%
1か月 パフォーマンス:
+39.01%
6か月 パフォーマンス:
+90.29%
1年 パフォーマンス:
+232.20%
1日の値動き範囲:
$1.72
$2.00
1週間の範囲:
$1.66
$2.00
52週間の値動き範囲:
$0.515
$2.00
Ocugen Inc Stock (OCGN) Company Profile
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.96 | 608.82M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and Statistics - IndexBox
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria
Ocugen Q4 Earnings Call Highlights - Yahoo Finance
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative
OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView
Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative
Earnings Summary: Ocugen Q4 - Benzinga
BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView
Gene therapy push for blindness: how Ocugen plans to fund it - Stock Titan
OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Examining the Future: Ocugen's Earnings Outlook - Benzinga
OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks
Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com
Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - Bitget
Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharm - StreetInsider
Ocugen Advances Toward Key Regulatory Submission for Gene Therapy - AD HOC NEWS
How The Investment Story For Ocugen (OCGN) Is Shifting With New Data And Funding Moves - Yahoo Finance
Why Did OCGN Stock Rise Today? - Asianet Newsable
Investment Report: Is Ocugen Inc undervalued by DCF analysisJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Ocugen (OCGN) Expected to Announce Earnings on Wednesday - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results - MyChesCo
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):